NCT04318717View on ClinicalTrials.gov

Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 29, 2020

Primary Completion Date

February 12, 2027

Study Completion Date

February 12, 2029

Conditions
Mucosal Melanoma of the Head and Neck
Interventions
DRUG

Pembrolizumab

Pembrolizumab is commercially available

RADIATION

Hypofractionated radiation therapy

It is preferred to leave at least 48 hours between fractions. Daily imaging to verify accurate set-up is mandatory.

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER